+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Soluble CD40 ligand release in patients with stable coronary artery disease during elective stent implantation: effect of drug-eluting stent over bare metal stent



Soluble CD40 ligand release in patients with stable coronary artery disease during elective stent implantation: effect of drug-eluting stent over bare metal stent



Turk Kardiyoloji Dernegi Arsivi 41(8): 675-682



We aimed to determine the effect of drug-eluting stent (DES) implantation on soluble CD40 ligand (sCD40L) levels in patients with stable coronary artery disease undergoing stent replacement. Eighty-nine consecutive patients (33 women, 56 men; mean age 61±10 years) with stable coronary artery disease undergoing stent replacement were recruited. Pre- and post-procedural blood samples were collected for sCD40L analysis, and differences in plasma levels were calculated and expressed as delta sCD40L. Total size and length of implanted stents and pre- and post-dilatation procedures were recorded for each patient, for possible impact on sCD40L release. Patients were followed for one year following procedures for possible adverse cardiac events such as death, myocardial infarction and revascularization. Forty-nine patients received bare metal stent (BMS) and 40 patients received DES. There were no differences between BMS- and DES-implanted patients in terms of age, stent size and length, and delta sCD40L plasma levels. Delta sCD40L was correlated only with total implanted stent length (r=0.374, p<0.001). Delta sCD40L levels were divided into quartiles for better determination of the procedural parameters that are effective on biomarker release. Total stent length (p=0.008), stent size (p=0.038) and pre-dilatation procedure (p=0.034) were the statistically differing parameters between delta sCD40L quartiles. Although statistically non-significant, all three adverse events were observed in patients with the highest quartile (p=0.179). Procedural sCD40L release did not differ between DES- and BMS-implanted stable coronary artery disease patients. Total implanted stent length, stent size and pre-dilatation procedure were the influential parameters on procedural sCD40L release.

(PDF emailed within 1 workday: $29.90)

Accession: 055840951

Download citation: RISBibTeXText

PMID: 24351940


Related references

Impact of stent diameter and length on in-stent restenosis after drug eluting stent versus bare metal stent implantation in patients needing large coronary stents. European Heart Journal 34(Suppl 1): 1046-1046, 2013

AS-203 Comparison of Clinical Outcome between Bare-Metal Stent and Drug-Eluting Stent Implantation in Large Vessel Coronary Artery Disease. American Journal of Cardiology 107(8-Supp-S): 76-0, 2011

Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation. American Heart Journal 155(3): 553-561, 2008

Comparison of long-term results of drug-eluting stent and bare metal stent implantation in heart transplant recipients with coronary artery disease. Kardiologia Polska 68(2): 131-134, 2010

Comparison of long-term results of drug-eluting stent and bare metal stent implantation in heart transplant recipients with coronary artery disease. Transplantation Proceedings 39(9): 2859-2861, 2007

Hybrid strategy of a bare metal stent combined with a drug-eluting stent versus exclusive drug-eluting stent implantation for multivessel percutaneous coronary intervention. Eurointervention 6(9): 1085-1090, 2011

A new polymer-free drug-eluting stent with nanocarriers eluting sirolimus from stent-plus-balloon compared with bare-metal stent and with biolimus A9 eluting stent in porcine coronary arteries. Cardiovascular Diagnosis and Therapy 5(2): 113-121, 2015

AS-220 Comparison of Mid-term Angiographic Assessments between Bare Metal Stent (S-stent) and Drug-Eluting (Paclitaxel-Eluting) Stent in the Large Coronary Artery. American Journal of Cardiology 107(8-Supp-S): 82-83, 2011

Influence of proximal drug eluting stent (DES) on distal bare metal stent (BMS) in multi-stent implantation strategies in coronary arteries. Medical Engineering and Physics 37(9): 840-844, 2016

The risk of definitive stent thrombosis is increased after "off-label" stent implantation irrespective of drug-eluting stent or bare-metal stent use. Clinical Research in Cardiology 98(9): 549-554, 2009

Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent. Journal of Zhejiang University. Science. B 11(8): 553-560, 2010

Bare metal stent implantation in large-sized unprotected left main coronary artery stenosis in the drug-eluting stent era. Cardiovascular Intervention and Therapeutics 25(2): 65-71, 2010

A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). Journal of the American College of Cardiology 63(14): 1378-1386, 2014

Comparison of Drug-Eluting Stent with Bare-Metal Stent Implantation in Femoropopliteal Artery Disease: A Systematic Review and Meta-Analysis. Annals of Vascular Surgery 50: 96-105, 2018

IVUS-guided management of late stent malaposition with peri-stent restenosis with coronary artery aneurysm following drug-eluting stent implantation (paxlitaxel-eluting stent). Journal of Invasive Cardiology 21(5): E87-E90, 2009